Description | J. Craig Venter Institute, La Jolla, CA 92137, USA; mpmviedma@gmail.com (M.d.P.M.V.);
gtan@jcvi.org (G.S.T.)
2 J. Craig Venter Institute, Rockville, MD 20850, USA; spanossian@student.umgc.edu
3 Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA;
kennedylincoln@icloud.com
4 Instituto de Investigacion en Microbiologia, Universidad Nacional Autónoma de Honduras,
Tegucigalpa, Honduras; kimfa_2010@hotmail.com (K.G.); isismaria_rodas@hotmail.com (I.F.);
lparham29@hotmail.com (L.P.); ivettelorenzana@yahoo.com (I.L.)
5 Institute Goncalo Moniz, Fiocruz Bahia, Salvador 40296-710, Brazil; laisepaixao@live.com (L.d.M.);
lilliangomes20@gmail.com (L.N.G.); vsboaventura@gmail.com (V.B.)
6 Departmento de Enfermedades Infecciosas e Inmunología Pediátrica, Escuela de Medicina, Pontificia
Universidad Católica de Chile, Santiago H955+8Q, Chile; tcgarcia21@gmail.com (T.G.-S.); cperret@uc.cl (C.P.);
rmedinai@uc.cl (R.A.M.)
7 Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology,
La Jolla, CA 92037, USA; dweiskopf@lji.org (D.W.); alex@lji.org (A.S.); dharshan_fom@kdu.ac.lk (A.D.D.S.)
8 Department of Medicine, Infectious Diseases Division, University of California San Diego,
La Jolla, CA 92037, USA
9 Hospital Universitário-Universidade Federal do Maranhão, São Luís 65000-000, Brazil;
aamouradasilva@gmail.com
10 Faculdade de Medicina da Bahia-Universidade Federal da Bahia, Salvador 40000-000, Brazil;
kakrami@ucsd.edu (K.M.A.); ricardo.khouri@fiocruz.br (R.K.)
11 Instituto Nacional de Nutricion, Universidad Nacional Autonoma de Mexico, Mexico City 04510, Mexico;
gmrps@unam.mx
12 Department of Medicine, University of California San Diego, La Jolla, CA 92037, USA
13 Genetech Research Institute, Colombo 00800, Sri Lanka
14 Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University,
Ratmalana 10390, Sri Lanka
15 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
16 Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine,
Aurora, CO 80045, USA; daniel.olson@childrenscolorado.org | pt_BR |
Abstract | Zika virus (ZIKV) is a mosquito-borne Flavivirus with a positive-sense RNA genome, which
are generally transmitted through the bite of an infected Aedes mosquito. ZIKV infections could be
associated with neurological sequelae that, and otherwise produces similar clinical symptoms as other
co-circulating pathogens. Past infection with one member of the Flavivirus genus often induces crossreactive
antibodies against other flaviruses. These attributes complicate the ability to differentially
diagnose ZIKV infection from other endemic mosquito-borne viruses, making it both a public health
issue as well as a diagnostic challenge. We report the results from serological analyses using arbovirusspecific
peptides on 339 samples that were previously collected from 6 countries. Overall, we found
that our multiplexed peptide-based ELISA was highly efficient for identifying ZIKV antibodies as
early as 2 weeks post infection, and that it correlates with microneutralization, plaque reduction
neutralization tests (PRNTs) and commercial tests for ZIKV in previously characterized samples. We
observed that seropositivity varied by patient cohort, reflecting the sampling period in relation to the 2015–2016 ZIKV outbreak. This work evaluates the accuracy, specificity, and sensitivity of our
peptide-based ELISA method for detecting ZIKV antibodies from geographically diverse regions.
These findings can contribute to ongoing serological methods development and can be adapted for
use in future studies. | pt_BR |